drugset / Trial / NCT02235259

Efficacy and Safety of XG-104 for the Treatment of Dry Eye

NCT02235259 ↗

Phase 2 Completed 260 enrolled Xigen SA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to assess the safety and efficacy of XG-104 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye after a 4 week Three Times a Day (TID) treatment period

Timeline

Start
2014-09
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject XG-104 Unknown — Other

Indications